KVD001 Protects DME Patients From Losing Their Vision, Phase 2 Trial Shows
KVD001 safely protects people with diabetic macular edema from losing their vision, according to a Phase 2 trial conducted by the treatment’s developer, KalVista Pharmaceuticals. DME is a form of angioedema that is caused by the leaking of blood vessels which lead to fluid accumulating in the…